[
  {
    "ts": null,
    "headline": "Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates",
    "summary": "Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved development milestone for masked antibody-based program under AbbVie agreement Nominated development candidate for wholly-owned masked T cell engager program targeting CLDN18.2 Appoints Sara Bonstein as chair of board of directors WALTHAM, Mass., Jan. 08,",
    "url": "https://finnhub.io/api/news?id=fb9181de4cb8f5780b147e3ade27cfa49dbf27947faf21e072c0710c8a20d478",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767879000,
      "headline": "Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates",
      "id": 138036627,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved development milestone for masked antibody-based program under AbbVie agreement Nominated development candidate for wholly-owned masked T cell engager program targeting CLDN18.2 Appoints Sara Bonstein as chair of board of directors WALTHAM, Mass., Jan. 08,",
      "url": "https://finnhub.io/api/news?id=fb9181de4cb8f5780b147e3ade27cfa49dbf27947faf21e072c0710c8a20d478"
    }
  }
]